Mavenclad, a medication used to treat certain forms of multiple sclerosis (MS), can cause hair loss, but this side effect is relatively uncommon and usually not severe. Hair loss occurs in about 3% of people taking Mavenclad, making it an infrequent but recognized side effect. When it does happen, the hair thinning is typically temporary and tends to improve after the treatment course is completed.
To understand why Mavenclad might cause hair loss, it helps to know how the drug works. Mavenclad is an immunosuppressive medication, meaning it reduces the activity of the immune system. MS is an autoimmune disease where the immune system mistakenly attacks the nervous system, so calming this immune response is the goal of treatment. However, because the immune system also plays a role in maintaining healthy hair follicles, suppressing it can sometimes disrupt the normal hair growth cycle, leading to hair thinning or shedding.
Hair loss from Mavenclad is generally not the same as complete baldness but rather a noticeable thinning or shedding of hair. This can be distressing for patients, especially since MS itself and other MS treatments can also contribute to hair changes. For example, some other disease-modifying therapies (DMTs) for MS, like teriflunomide, have a higher incidence of hair thinning. But with Mavenclad, the percentage of patients experiencing this side effect is lower.
The timing of hair loss with Mavenclad can vary. Some patients might notice it during or shortly after their treatment cycles. Mavenclad is given in short courses over two years rather than continuously, which means any side effects, including hair loss, often appear during treatment periods and then gradually resolve. Because the drug affects the immune system in a way that is not constant, hair regrowth usually occurs once the immune system recovers after treatment.
It’s important to note that hair loss in people with MS can have multiple causes. MS itself, stress, nutritional deficiencies, other medications, or underlying health conditions can all contribute to hair thinning. Therefore, if someone on Mavenclad notices hair loss, it’s essential to discuss it with their neurologist or healthcare provider to determine the cause and appropriate management. Stopping or changing the medication without medical advice is not recommended because the benefits of controlling MS relapses often outweigh the temporary discomfort of hair thinning.
In terms of managing hair loss while on Mavenclad, there are no specific treatments proven to prevent it, but general hair care practices can help minimize damage. These include gentle hair washing, avoiding harsh chemicals or heat styling, and maintaining a balanced diet rich in vitamins and minerals that support hair health. If hair loss is significant or persistent, a healthcare provider might evaluate for other causes or consider alternative MS treatments.
Mavenclad’s safety profile means it is usually reserved for patients who have not responded well to other MS medications or cannot tolerate them. Besides hair loss, common side effects include upper respiratory infections, headaches, and decreased white blood cell counts. Because it suppresses the immune system, patients must be screened for infections and certain cancers before starting treatment. Women of childbearing potential must use effective contraception during and for six months after treatment due to the risk of fetal harm.
In summary, while Mavenclad can cause hair loss, this side effect is relatively rare and usually temporary. The drug’s immunosuppressive action can disrupt hair growth cycles, but hair typically regrows after treatment ends. Patients experiencing hair thinning should consult their healthcare providers to ensure proper diagnosis and management, balancing the need to control MS with the desire to minimize side effects.
